Tarek Sahmoud

19.0k total citations · 8 hit papers
130 papers, 11.3k citations indexed

About

Tarek Sahmoud is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tarek Sahmoud has authored 130 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pulmonary and Respiratory Medicine, 76 papers in Oncology and 32 papers in Molecular Biology. Recurrent topics in Tarek Sahmoud's work include Advanced Breast Cancer Therapies (44 papers), Cancer Treatment and Pharmacology (43 papers) and PI3K/AKT/mTOR signaling in cancer (25 papers). Tarek Sahmoud is often cited by papers focused on Advanced Breast Cancer Therapies (44 papers), Cancer Treatment and Pharmacology (43 papers) and PI3K/AKT/mTOR signaling in cancer (25 papers). Tarek Sahmoud collaborates with scholars based in Belgium, United States and France. Tarek Sahmoud's co-authors include A. Kirkpatrick, Laurence Collette, Aman U. Budzar, Joanna Houghton, M Baum, J Cuzick, JF Forbes, J.G.M. Klijn, J.-L. Lefebvre and B Luboïnski and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Tarek Sahmoud

124 papers receiving 11.0k citations

Hit Papers

Anastrozole alone or in c... 1996 2026 2006 2016 2002 1997 1996 1999 2010 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
    2002 1.5k citations Tarek Sahmoud et al. The Lancet profile →
  2. Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus
    1997 1.0k citations Jean-François Bosset, M Gignoux et al. New England Journal of Medicine profile →
  3. Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial
    1996 971 citations A. Kirkpatrick, Tarek Sahmoud et al. JNCI Journal of the National Cancer Institute profile →
  4. Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region
    1999 918 citations Jean H. G. Klinkenbijl, Johannes Jeekel et al. profile →
  5. Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
    2010 725 citations Tarek Sahmoud, David Neal Franz et al. New England Journal of Medicine profile →
  6. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
    2013 629 citations Michael Frost, Е. Д. Белоусова et al. The Lancet profile →
  7. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
    2012 578 citations David Neal Franz, Е. Д. Белоусова et al. The Lancet profile →
  8. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
    2013 379 citations Tarek Sahmoud, David Lebwohl et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tarek Sahmoud Belgium 41 5.1k 4.9k 3.1k 2.3k 2.1k 130 11.3k
Lori J. Wirth United States 48 4.3k 0.8× 2.4k 0.5× 1.8k 0.6× 1.1k 0.5× 2.0k 1.0× 260 9.9k
Samuel Hellmän United States 57 3.8k 0.7× 3.0k 0.6× 2.1k 0.7× 805 0.4× 1.4k 0.7× 238 10.8k
Bernard Asselain France 59 5.2k 1.0× 2.1k 0.4× 1.8k 0.6× 1.1k 0.5× 2.0k 1.0× 323 11.0k
Martee L. Hensley United States 55 4.2k 0.8× 4.7k 1.0× 1.6k 0.5× 1.3k 0.6× 1.8k 0.9× 223 13.3k
Keyue Ding Canada 45 8.1k 1.6× 8.4k 1.7× 1.7k 0.5× 641 0.3× 3.4k 1.6× 218 14.5k
Rossella Elisei Italy 72 5.5k 1.1× 2.2k 0.5× 6.2k 2.0× 3.4k 1.5× 4.5k 2.2× 370 23.3k
Alphonse G. Taghian United States 59 5.2k 1.0× 1.8k 0.4× 3.3k 1.1× 680 0.3× 859 0.4× 268 11.7k
Marie Overgaard Denmark 55 4.3k 0.8× 2.6k 0.5× 4.0k 1.3× 673 0.3× 1.1k 0.5× 139 12.5k
Maciej Krzakowski Poland 43 7.6k 1.5× 6.4k 1.3× 944 0.3× 593 0.3× 2.2k 1.1× 261 11.4k
Arnoud J. Templeton Switzerland 40 5.6k 1.1× 2.6k 0.5× 1.5k 0.5× 301 0.1× 1.1k 0.5× 152 8.6k

Countries citing papers authored by Tarek Sahmoud

Since Specialization
Citations

This map shows the geographic impact of Tarek Sahmoud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarek Sahmoud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarek Sahmoud more than expected).

Fields of papers citing papers by Tarek Sahmoud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarek Sahmoud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarek Sahmoud. The network helps show where Tarek Sahmoud may publish in the future.

Co-authorship network of co-authors of Tarek Sahmoud

This figure shows the co-authorship network connecting the top 25 collaborators of Tarek Sahmoud. A scholar is included among the top collaborators of Tarek Sahmoud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarek Sahmoud. Tarek Sahmoud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schilder, Russell J., Mark S. Shahin, Mitchell I. Edelson, et al.. (2023). OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.. Journal of Clinical Oncology. 41(16_suppl). 5601–5601. 2 indexed citations
2.
Gnant, Michael, José Baselga, Hope S. Rugo, et al.. (2013). Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. JNCI Journal of the National Cancer Institute. 105(9). 654–663. 77 indexed citations
3.
4.
Ejlertsen, Bent, Guy Jérusalem, Sara A. Hurvitz, et al.. (2013). Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6. Open Repository and Bibliography (University of Liège). 2 indexed citations
5.
Hurvitz, Sara A., Florence Dalenc, Mario Campone, et al.. (2013). A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment. 141(3). 437–446. 58 indexed citations
6.
7.
Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2012). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 381(9861). 125–132. 578 indexed citations breakdown →
8.
Piccart, Martine, Shinzaburo Noguchi, Kathleen I. Pritchard, et al.. (2012). Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology. 30(15_suppl). 559–559. 33 indexed citations
9.
Pritchard, Kathleen I., Howard A. Burris, Hope S. Rugo, et al.. (2012). Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.. Journal of Clinical Oncology. 30(15_suppl). 551–551. 1 indexed citations
10.
Anderson, Thomas, J. Michael Dixon, Melissa K. Stuart, Tarek Sahmoud, & William R. Miller. (2002). Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. British Journal of Cancer. 87(3). 334–338. 32 indexed citations
11.
Bonneterre, J., Aman U. Buzdar, John F. R. Robertson, et al.. (2001). Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92(9). 2247–2258. 437 indexed citations
12.
Denoux, Yves, Paulette Herlin, Marc J. van de Vijver, et al.. (2000). Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial. Cancer. 89(8). 1748–1757. 31 indexed citations
13.
Clahsen, P C, C J van de Velde, Christian Duval, et al.. (1998). p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.. Journal of Clinical Oncology. 16(2). 470–479. 144 indexed citations
14.
Curran, Desmond, Tarek Sahmoud, P. Therasse, et al.. (1998). Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.. Journal of Clinical Oncology. 16(1). 145–152. 404 indexed citations
15.
Bosset, Jean-François, M Gignoux, Jean–Pierre Triboulet, et al.. (1997). Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus. New England Journal of Medicine. 337(3). 161–167. 1025 indexed citations breakdown →
16.
Zandwijk, Nico van, Harry J.M. Groen, Pieter E. Postmus, et al.. (1997). Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase iii study of the eortc lung cancer cooperative group. European Journal of Cancer. 33(11). 1759–1766. 40 indexed citations
17.
Nitti, Donato, J. Wils, Tarek Sahmoud, et al.. (1997). Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Journal of Cancer. 33(8). 1209–1215. 34 indexed citations
18.
Klinkenbijl, Jean H. G., Tarek Sahmoud, Renée van Pel, et al.. (1997). Radiotherapy and 5-FU after curative resection for the cancer of the pancreas and peri-ampullary region: A phase III trial of the EORTC GITCCG. European Journal of Cancer. 33. S274–S274. 18 indexed citations
19.
Splinter, Ted A.W., M. Pavone‐Macaluso, Didier Jacqmin, et al.. (1996). Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: Prognostic factor analysis. European Journal of Cancer. 32(7). 1129–1134. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lori J. Wirth Breakdown of academic impact, for papers by Samuel Hellmän Breakdown of academic impact, for papers by Bernard Asselain Breakdown of academic impact, for papers by Martee L. Hensley Breakdown of academic impact, for papers by Keyue Ding Breakdown of academic impact, for papers by Rossella Elisei Breakdown of academic impact, for papers by Alphonse G. Taghian Breakdown of academic impact, for papers by Marie Overgaard Breakdown of academic impact, for papers by Maciej Krzakowski Breakdown of academic impact, for papers by Arnoud J. Templeton
Rankless by CCL
2026